RT Journal Article
SR Electronic
T1 Soluble immune checkpoints are dysregulated in COVID-19 and heavy alcohol users with HIV infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.22.21268218
DO 10.1101/2021.12.22.21268218
A1 Li, Wei
A1 Syed, Fahim
A1 Yu, Richard
A1 Yang, Jing
A1 Xia, Ying
A1 Relich, Ryan F.
A1 Zhang, Shanxiang
A1 Khalili, Mandana
A1 Huang, Laurence
A1 Kacena, Melissa A.
A1 Zheng, Xiaoqun
A1 Yu, Qigui
YR 2021
UL http://medrxiv.org/content/early/2021/12/30/2021.12.22.21268218.abstract
AB Immune checkpoints (ICPs) consist of paired receptor-ligand molecules that exert inhibitory or stimulatory effects on immune defense, surveillance, regulation, and self-tolerance. ICPs exist in both membrane and soluble forms in vivo and in vitro. Imbalances between inhibitory and stimulatory membrane-bound ICPs (mICPs) in malignant cells and immune cells in the tumor immune microenvironment (TIME) have been well documented. Blockades of inhibitory mICPs have emerged as an immense breakthrough in cancer therapeutics. However, the origin, structure, production regulation, and biological significance of soluble ICPs (sICPs) in health and disease largely remains elusive. Soluble ICPs can be generated through either alternative mRNA splicing and secretion or protease-mediated shedding from mICPs. Since sICPs are found in the bloodstream, they likely form a circulating immune regulatory system. In fact, there is increasing evidence that sICPs exhibit biological functions including (1) regulation of antibacterial immunity, (2) interaction with their mICP compartments to positively or negatively regulate immune responses, and (3) competition with their mICP compartments for binding to the ICP blocking antibodies, thereby reducing the efficacy of ICP blockade therapies. Here, we summarize current data of sICPs in cancer and infectious diseases. We particularly focus on sICPs in COVID-19 and HIV infection as they are the two ongoing global pandemics and have created the world’s most serious public health challenges. A “storm” of sICPs occurs in the peripheral circulation of COVID-19 patients and is associated with the severity of COVID-19. Similarly, sICPs are highly dysregulated in people living with HIV (PLHIV) and some sICPs remain dysregulated in PLHIV on antiretroviral therapy (ART), indicating these sICPs may serve as biomarkers of incomplete immune reconstitution in PLHIV on ART. We reveal that HIV infection in the setting of alcohol abuse exacerbates sICP dysregulation as PLHIV with heavy alcohol consumption have significantly elevated plasma levels of many sICPs. Thus, both stimulatory and inhibitory sICPs are present in the bloodstream of healthy people and their balance can be disrupted under pathophysiological conditions such as cancer, COVID-19, HIV infection, and alcohol abuse. There is an urgent need to study the role of sICPs in immune regulation in health and disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the National Institute on Alcohol Abuse and Alcoholism (grant number UH2AA026218 to Q. Y.); the Bill and Melinda Gates Foundation (grant number OPP1035237 to Q. Y.); the Indiana Biobank and the Indiana Clinical and Translational Sciences Institute funded by the NIH (grant number UL1TR002529); and the National Center for Advancing Translational Sciences, Clinical and Translational Sciences Award. Dr. Khalili was also in part supported by the National Institute of Alcohol Abuse and Alcoholism (grant number K24AA022523).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Study Subjects and Ethical Considerations. This study was performed with the approval of the Institutional Review Board at Indiana University School of Medicine and University of California San Francisco. Blood samples were drawn after each participant provided a written informed consent form.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsALDalcohol-associated liver diseaseAPCantigen-presenting cellARTantiretroviral therapyBTLAB- and T-lymphocyte attenuatorCTLA-4cytotoxic T-lymphocyte-associated protein 4GITRglucocorticoid-induced tumor necrosis factor receptor-related proteinGITRLglucocorticoid-induced tumor necrosis factor receptor-ligandHBVhepatitis B virusHChealthy controlHCChepatocellular carcinomaHIVhuman immunodeficiency virusHVEMherpesvirus entry mediatorICPimmune checkpointICOSinducible T-cell costimulatorLAG-3lymphocyte-activation gene 3LIGHThomologous to lymphotoxin, exhibits inducible expression and competes with HSV glycoprotein D for binding to herpesvirus entry mediator, a receptor expressed on T lymphocytesmICPmembrane-bound immune checkpointPD-1programmed death 1PD-L1programmed death-ligand 1PLHIVpeople living with HIVsICPsoluble immune checkpointTBtuberculosisTCRT cell receptorTIM-3T-cell immunoglobulin and mucin domain 3TIMEtumor immune microenvironmentTNFRSFtumor necrosis factor receptor superfamilyTLR-2Toll-like receptor-2